Sagimet Biosciences Reports Significant Clinical Progress and Financial Milestones in April 2026 Update

Key Highlights for Investors

• Denifanstat achieves major Phase 3 success in moderate to severe acne vulgaris in China
• US Phase 3 clinical trial for denifanstat in moderate to severe acne planned for 2H 2026
• TVB-3567, a follow-on FASN inhibitor, advances into first-in-human Phase 1 clinical study
• Strong cash position and \$175M underwritten Series A offering to fund operations through 2028
• Robust intellectual property portfolio with potential exclusivity into 2046 and beyond

Clinical Development and Pipeline Progress

Denifanstat: A Differentiated Oral FASN Inhibitor

• Sagimet’s lead asset, denifanstat, is a novel fatty acid synthase (FASN) inhibitor with a unique mechanism of action targeting metabolic dysfunction in diseases such as acne and MASH (metabolic dysfunction-associated steatohepatitis).
• Denifanstat met all primary and secondary endpoints in a 480-patient Phase 3 trial for moderate to severe acne vulgaris in China, conducted by license partner Ascletis.
• The primary efficacy outcomes included:
  • 33.2% of patients achieved treatment success (IGA score improvement of at least 2 points and IGA 0 or 1 at week 12) vs. 14.6% for placebo (p<0.0001).
  • 57.4% reduction in total lesion count compared to 35.4% for placebo.
  • 63.5% reduction in inflammatory lesion count vs. 43.2% for placebo.
  • 51.9% reduction in non-inflammatory lesion count vs. 28.9% for placebo.
• Safety Profile: Denifanstat was generally well-tolerated. The incidence of treatment-emergent adverse events (TEAEs) was similar to placebo. The most common TEAEs (≥5%) were dry eye (10.9% vs. 9.2% for placebo) and dry skin (6.3% vs. 2.9% for placebo). All events were mild or moderate, with no serious denifanstat-related AEs or deaths.
• An open-label extension study (52 weeks) confirmed the favorable safety profile, with only mild or moderate drug-related adverse events and only one case of temporary hair thinning.
• Ascletis submitted an NDA for denifanstat to China’s NMPA in December 2025 for moderate to severe acne, which was accepted.
• Sagimet plans to launch a US Phase 3 trial in 2H 2026, following regulatory consultation. The planned US trial will enroll 800 patients, with a 2:1 randomization (533 on denifanstat, 267 on placebo), assessing IGA success and reduction in lesion counts at week 12, plus long-term safety in an open-label extension to 52 weeks.

TVB-3567: Next-Generation FASN Inhibitor

• TVB-3567, Sagimet’s follow-on FASN inhibitor, received IND clearance in March 2025.
• The first-in-human (FIH) Phase 1 trial started in June 2025, assessing safety, tolerability, PK, and pharmacodynamics (including sebum analysis) in healthy volunteers with or without acne.
• The Phase 1 trial is expected to support a Phase 2 Proof-of-Concept trial in moderate to severe acne, targeted to initiate in 2H 2026 pending regulatory feedback.
• A topical formulation of TVB-3567 is also in preclinical development for acne.

Denifanstat in MASH (Metabolic Dysfunction-Associated Steatohepatitis)

• Denifanstat met both primary endpoints (including significant reduction in fibrosis) in a Phase 2b trial in patients with F2/F3 MASH and received FDA Breakthrough Therapy designation.
• Sagimet completed a Phase 1 PK study combining denifanstat and resmetirom by December 2025, with preclinical data showing synergistic effects. A Phase 2 readiness package is expected by end of 2026, but further MASH development is contingent on non-dilutive funding.

Market Opportunity and Competitive Positioning

• The global acne market is projected to reach \$20 billion by 2034, with approximately 50 million Americans affected annually. Of these, 10 million have moderate to severe disease, suitable for oral therapies like FASN inhibitors.
• Current treatments for moderate to severe acne include oral antibiotics, hormonal agents, and isotretinoin, but there remains an unmet need for novel, well-tolerated, and effective oral therapies. FASN inhibitors offer a new mechanism, targeting sebum production and inflammation.
• Sagimet’s FASN inhibitor portfolio is well-protected, with:
  • Denifanstat composition of matter patent expiring in 2032 (potential extension to 2037).
  • TVB-3567 patent expiring in 2035 (potential extension to 2038) and method of use for acne filed in 2025 (potential expiry in 2046).
  • Combination IP for denifanstat and resmetirom potentially lasting through 2044–2048.

Financial Position and Capitalization

• Sagimet had \$104.5 million in cash, cash equivalents, and marketable securities as of March 31, 2026 (unaudited and preliminary). Cash as of December 31, 2025, was \$113.1 million.
• In April 2026, Sagimet announced a \$175 million underwritten offering of Series A Common Stock. The proceeds, together with current cash and securities, are expected to fund operations through 2028, including the readout of the planned US Phase 3 denifanstat acne study.

Leadership Team

• The company is led by a seasoned management team with over 20 years’ average experience in biotech, pharma, clinical development, medical affairs, R&D, IP, and commercialization.

Key Shareholder Notes & Price-Sensitive Information

• Denifanstat’s Phase 3 success in China and NMPA NDA acceptance, combined with an imminent US Phase 3 trial, is a significant value driver for Sagimet.
• The \$175 million capital raise substantially extends Sagimet’s operational runway, reducing financing risk through 2028 and enabling key value-driving milestones.
• Clinical progress with TVB-3567 and ongoing trial readouts, including potential progression to Phase 2 in 2026, represent important future catalysts.
• Robust IP portfolio secures market exclusivity for potentially two decades, supporting long-term value creation.
• Further MASH development, including potential for combination therapies, is pending non-dilutive funding, which may provide upside if secured.

Conclusion

The breadth and depth of Sagimet’s clinical pipeline, recent clinical successes, robust financial position, and strong intellectual property portfolio position the company for significant potential value creation. Investors should pay close attention to upcoming US Phase 3 trial initiation for denifanstat in acne, readouts from TVB-3567 clinical studies, and potential business development milestones, all of which have the potential to materially impact Sagimet’s share price.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are encouraged to conduct their own due diligence and consult with professional advisors prior to making investment decisions. Forward-looking statements are subject to significant risks and uncertainties which may cause actual results to differ materially from those expressed or implied herein.

View Sagimet Biosciences Inc. Historical chart here